Categories
Art & Life Business Economics Lifestyle Regulations & Security

Best’s Review looks closely at insurance expense efficiency

OLDWICK, N.J. — (BUSINESS WIRE) — In a new article, Best’s Review speaks with industry experts about the challenges of reducing the expense ratio.

 

According to Bill Pieroni, president and chief executive officer for ACORD, “What we’ve found and seen over the last several years is that the sustainable value carriers are able to have a lower-than-average loss adjustment expense and a lower-than-average pure loss ratio.”

A new Best’s Special Report notes some improvement, as the industry’s average underwriting expense ratio decreased to 26.3% in 2021 from 28.0% in 2011, and the net general expense ratio declined to 6.5% in 2021 from 7.1% in 2011. Read the full story, “Insurers Find Ways to Decrease the Underwriting Expense Ratio.”

 

Best’s Review is AM Best’s monthly insurance magazine, covering emerging issues and trends and evaluating their impact on the marketplace. The complete content of Best’s Review is available here.

 

AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit www.ambest.com.

Copyright © 2023 by A.M. Best Company, Inc. and/or its affiliates. ALL RIGHTS RESERVED.

Contacts

Patricia Vowinkel

Executive Editor, Best’s Review®
+1 908 439 2200, ext. 5540

patricia.vowinkel@ambest.com

Categories
Art & Life Business Culture Economics Lifestyle Science

Siegel Egg Co. names Matt Whitney as new CEO

BETHESDA, Md. & EVANSTON, Ill. — (BUSINESS WIRE) — Siegel Egg Co. “(Siegel” or “the Company)” has named Matt Whitney as Chief Executive Officer.

 

Whitney succeeds Matt Saunders, who will retire with this transition. Siegel is a portfolio company of Rotunda Capital Partners “(Rotunda),” a middle-market private equity firm investing in family and founder-owned value-added distributors.


“I am thrilled to bring Matt onto our team,” Saunders said.

 

“We have been actively searching for the right leader to take the baton from me and drive Siegel to future heights. With Rotunda’s continued backing, Matt’s successful background in the food distribution industry will enable us to deliver significant value to our customers and vendor partners while pursuing a multitude of growth opportunities.”

 

“We are excited to welcome Matt to Siegel,” said Dan Lipson, Managing Partner at Rotunda.

 

“Siegel is a regional leader that is poised for accelerated growth, and Matt’s leadership and experience are exactly what we need to continue building on the Company’s strong history and dedication to customer service.”

 

In addition to the appointment of Matt, Ken Siegel, who ran the Company for over 30 years and is a significant stakeholder, will re-engage with the Company as a Senior Advisor to the leadership team for this next stage of growth.

 

He said, “Siegel has been in my family for almost 100 years, and I couldn’t be more excited to have Matt join the team as the next leader of the business.”

 

Whitney has been a leader in the food distribution industry for over a decade. He joins Siegel after serving as Chief Growth Officer of UNFI, the largest publicly traded wholesale distributor of specialty food in the United States. Prior to that, he spent almost eight years at Sysco, most recently as Corporate Vice President of Field Transformation and Executive Vice President of the Boston Division. Prior to that, he was a Partner at the Lucas Group and Principal at the Parthenon Group. Whitney holds a BA from Tufts University and an MBA from the Tuck School of Business at Dartmouth College.

 

“I am excited to join an organization as respected as Siegel, with almost 100 years of history and reputation,” Whitney said. “I look forward to working closely with the Siegel team, Ken and Rotunda to engage with our customer and vendor partners to accelerate Siegel’s position as a leader in the industry.”

 

About Siegel Egg Co.

Founded in 1924, Siegel is a one of New England’s leading distributors of egg, dairy and bakery ingredients primarily serving commercial bakeries and food service institutions. The Company operates out of a single facility in Billerica, Mass., to distribute over 2,300 SKUs to customers in New England, Connecticut, New Jersey and New York. For more information, visit www.siegelegg.com.

 

About Rotunda Capital Partners

Rotunda Capital Partners is an operationally oriented private equity firm focused on transforming family-founder owned companies into dynamic, data-driven platforms able to achieve and manage significant growth. Since its founding in 2009, Rotunda has partnered with management teams to build great businesses within three primary sectors: value-added distribution, asset-light logistics and industrial, business and residential services. Rotunda strives to achieve replicable results by implementing its Rotunda Performance System to create strategic alignment, develop lean processes and create robust, data-driven infrastructures. For more information, visit www.rotundacapital.com.

Contacts

Jill Lafferty

Rotunda Capital Partners

(847) 280-1295

jill@rotundacapital.com

Categories
Business Economics Lifestyle Regulations & Security

Catalent recommends stockholders reject mini-tender offer from TRC Capital Investment Corporation

SOMERSET, N.J. — (BUSINESS WIRE) — Catalent, Inc. (“Catalent”) (NYSE: CTLT) has been notified of an unsolicited “mini-tender offer” by TRC Capital Investment Corporation (“TRC”) to purchase up to 2,000,000 shares of Catalent’s common stock at a price of $42.95 per share in cash. TRC’s offer price is approximately 4.43% lower than the $44.94 closing price of Catalent’s common stock on April 24, 2023, the last trading day prior to the date of the mini-tender offer (April 25, 2023).

 

Catalent does not endorse TRC’s unsolicited mini-tender offer and recommends that stockholders do not tender their shares in response to this unsolicited mini-tender offer because the offer is at a price below the current market price of Catalent’s common stock and is subject to numerous other conditions.

 

Catalent is not affiliated or associated in any way with TRC, its mini-tender offer or the offer documentation. TRC has made similar mini-tender offers for shares of other companies. Mini-tender offers seek to acquire not more than 5 percent of a company’s shares outstanding, thereby avoiding many disclosure and procedural requirements of the U.S. Securities and Exchange Commission (the “SEC”) that are designed to protect investors. As a result, mini-tender offers do not provide investors with the same level of protection as provided by larger tender offers under United States federal securities laws.

 

The SEC has issued “Tips for Investors” regarding mini-tender offers, cautioning investors that some bidders, in making the offers at below-market prices, are “hoping that they will catch investors off guard if the investors do not compare the offer price to the current market price.” The SEC’s advisory may be found on the SEC website at http://www.sec.gov/investor/pubs/minitend.htm.

 

Catalent urges stockholders to obtain current market quotations for their shares of common stock, to consult their broker or financial advisor, and to exercise caution with respect to TRC’s mini-tender offer.

 

Catalent recommends that stockholders who have not responded to TRC’s mini-tender offer take no action. Catalent stockholders who have already tendered their shares may withdraw their shares by providing the written notice described in TRC’s offering documents prior to the expiration of the mini-tender offer, currently scheduled for 12:01 a.m., New York City time, on May 24, 2023, unless the offer is extended or earlier terminated.

 

Catalent urges brokers, dealers and other market participants to review the SEC’s recommendations to broker-dealers in these circumstances, which can be found on the SEC website at http://www.sec.gov/divisions/marketreg/minitenders/sia072401.htm.

 

Catalent requests that a copy of this news release be included with all distributions of materials relating to TRC’s mini-tender offer.

 

About Catalent

Catalent, Inc. (NYSE: CTLT), an S&P 500® company, is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply around 80 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of approximately 18,000 includes more than 3,000 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated nearly $5 billion in revenue in its 2022 fiscal year. For more information www.catalent.com.

Contacts

Investor Contact:

Paul Surdez, Catalent, Inc.

(732) 537-6325

investors@catalent.com

Media Contact:

Chris Halling

+44 (0)7580 041073

media@catalent.com

Categories
Business Economics Lifestyle Special/Sponsored Content

Amneal reports first quarter 2023 financial results

‒ Q1 2023 Net Revenue of $558 million; GAAP Net Loss of $7 million; Diluted Loss per Share of $0.05 ‒

‒ Adjusted EBITDA (1) of $116 million; Adjusted Diluted EPS (1) of $0.12 ‒

‒ Affirming 2023 Full Year Guidance ‒

 

BRIDGEWATER, N.J. — (BUSINESS WIRE) — Amneal Pharmaceuticals, Inc. (NYSE: AMRX) “(Amneal” or the “Company)” on Friday announced its actual results for the first quarter ended March 31, 2023.

 

“We are very pleased with our strong first quarter results and start to 2023. We are confident in our continued momentum driven by the broad-based strength of our diverse and increasingly complex generics portfolio, uptake of our new biosimilars, expansion of our AvKARE business, and the continued growth and potential of our specialty portfolio. Today we are also happy to announce the successful inspection of our fourth and largest injectables facility, and we are working closely with the U.S. FDA ahead of our June 30th PDUFA date for IPX203 in Parkinson’s. These are key building blocks and good indicators of our continued success as we execute our strategy, drive sustainable long-term growth, reduce debt, and create value for all of our stakeholders,” said Chirag and Chintu Patel, Co-Chief Executive Officers.

 

Net revenue in the first quarter of 2023 was $558 million, an increase of 12% compared to $498 million in the first quarter of 2022. The increase was driven by growth across all three business segments with strong performance across our complex Generics portfolio, growth of Rytary® and Unithroid® in Specialty, and continued expansion of AvKARE’s distribution channel.

 

Net loss attributable to Amneal Pharmaceuticals, Inc. was $7 million in the first quarter of 2023 compared to a net loss of $2 million in the first quarter of 2022. Adjusted EBITDA(1) in the first quarter of 2023 was $116 million, an increase of 16% compared to the first quarter of 2022, reflective of robust revenue performance and favorable operating expenses. Diluted loss per share in the first quarter of 2023 was $0.05 compared to a loss of $0.01 for the first quarter of 2022. Adjusted diluted EPS(1) in both the first quarter of 2023 and 2022 was $0.12.

 

(1) See “Non-GAAP Financial Measures” below.

Affirming Full Year 2023 Guidance

The Company is affirming its previously provided full year 2023 guidance.

Full Year 2023 Guidance

Net revenue

$2.25 billion – $2.35 billion

Adjusted EBITDA (1)

$500 million – $530 million

Adjusted diluted EPS (2)

$0.40 – $0.50

Operating cash flow (3)

$200 million – $230 million

Capital expenditures

$50 million – $60 million

Weighted average diluted shares outstanding (4)

Approximately 307 million

 

(1) Includes 100% of EBITDA from the AvKARE acquisition. See also “Non-GAAP Financial Measures” below.

(2) Accounts for 35% non-controlling interest in AvKARE. See also “Non-GAAP Financial Measures” below.

(3) Represents cash provided by operating activities. Guidance does not contemplate one time and non-recurring items such as legal settlements and other discrete items.

(4) Assumes the weighted average diluted shares outstanding of class A and class B common stock under the if-converted method.

 

Amneal’s 2023 estimates are based on management’s current expectations, including with respect to prescription trends, pricing levels, the timing of future product launches, the costs incurred and benefits realized of restructuring activities, and our long-term strategy. The Company’s financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The Company cannot provide a reconciliation between non-GAAP projections and the most directly comparable measures in accordance with GAAP without unreasonable efforts because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items required for the reconciliation. The items include, but are not limited to, acquisition-related expenses, restructuring expenses and benefits, asset impairments, legal settlements, and other gains and losses. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results.

 

Conference Call Information

Amneal will host a conference call and live webcast at 8:30 am Eastern Time on May 5, 2023 to discuss its results. The live webcast and presentation will be accessible through the Investor Relations section of the Company’s website at https://investors.amneal.com. To access the call through a conference line, dial 1 (833) 470-1428 (in the U.S.) or for a list of toll-free international numbers, visit this website: https://www.netroadshow.com/events/global-numbers?confId=49327. The access code for the call is 957420. A replay of the conference call will be posted shortly after the call and will be available for seven days. To access the replay, dial 1 (866) 813-9403 (in the U.S.) or for a list of toll-free international numbers, visit this website: https://www.netroadshow.com/events/global-numbers?confId=49327. The access code for the replay is 704782.

 

About Amneal

Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully integrated global essential medicines company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of approximately 270 generic and specialty pharmaceuticals, primarily within the United States. In its Generics segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit www.amneal.com.

 

Cautionary Statement on Forward-Looking Statements

Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations, including international expansion; expected or estimated operating results and financial performance; the Company’s growth prospects and opportunities as well as its strategy for growth; product development and launches; the successful commercialization and market acceptance of new products, and other non-historical statements. Words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and similar words, or the negatives thereof, are intended to identify estimates and forward-looking statements.

 

The reader is cautioned not to rely on these forward-looking statements. These forward-looking statements are based on current expectations of future events, including with respect to future market conditions, company performance and financial results, operational investments, business prospects, new strategies and growth initiatives, the competitive environment, and other events. If the underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Company.

 

Such risks and uncertainties include, but are not limited to: our ability to successfully develop, license, acquire and commercialize new products on a timely basis; the competition we face in the pharmaceutical industry from brand and generic drug product companies, and the impact of that competition on our ability to set prices; our ability to obtain exclusive marketing rights for our products; our ability to manage our growth through acquisitions and otherwise; our revenues are derived from the sales of a limited number of products, a substantial portion of which are through a limited number of customers; the continuing trend of consolidation of certain customer groups; our dependence on third-party suppliers and distributors for raw materials for our products and certain finished goods; our substantial amount of indebtedness and our ability to generate sufficient cash to service our indebtedness in the future, and the impact of interest rate fluctuations on such indebtedness; our ability to secure satisfactory terms when negotiating a refinancing or other new indebtedness; our dependence on third-party agreements for a portion of our product offerings; legal, regulatory and legislative efforts by our brand competitors to deter competition from our generic alternatives; risks related to federal regulation of arrangements between manufacturers of branded and generic products; our reliance on certain licenses to proprietary technologies from time to time; the significant amount of resources we expend on research and development; the risk of product liability and other claims against us by consumers and other third parties; risks related to changes in the regulatory environment, including U.S. federal and state laws related to healthcare fraud abuse and health information privacy and security and changes in such laws; changes to Food and Drug Administration product approval requirements; the impact of healthcare reform and changes in coverage and reimbursement levels by governmental authorities and other third-party payers; our potential expansion into additional international markets subjecting us to increased regulatory, economic, social and political uncertainties, including bank failures; our ability to identify, make and integrate acquisitions or investments in complementary businesses and products on advantageous terms; the impact of global economic, political or other catastrophic events; our ability to attract, hire and retain highly skilled personnel; our obligations under a tax receivable agreement may be significant; and the high concentration of ownership of our Class A Common Stock and the fact that we are controlled by the Amneal Group. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof.

 

Non-GAAP Financial Measures

This release includes certain non-GAAP financial measures, including EBITDA, adjusted EBITDA, and adjusted diluted EPS, which are intended as supplemental measures of the Company’s performance that are not required by or presented in accordance with GAAP. Adjusted diluted EPS reflects diluted earnings per share based on adjusted net income, which is net loss adjusted to (A) exclude (i) non-cash interest, (ii) GAAP provision for (benefit from) income taxes, (iii) amortization, (iv) stock-based compensation, (v) acquisition, site closure expenses, and idle facility expenses, (vi) restructuring and other charges, (vii) charges (credits) related to legal matters, including interest, net, (viii) asset impairment charges, (ix) regulatory approval milestone, (x) change in fair value of contingent consideration, (xi) other, (xii) net income attributable to non-controlling interests not associated with class B common stock, and (B) include non-GAAP provision for income taxes. Non-GAAP adjusted EPS is calculated assuming the weighted average diluted shares outstanding of class A and class B common stock under the if-converted method.

 

Management uses these non-GAAP measures internally to evaluate and manage the Company’s operations and to better understand its business because they facilitate a comparative assessment of the Company’s operating performance relative to its performance based on results calculated under GAAP. These non-GAAP measures also isolate the effects of some items that vary from period to period without any correlation to core operating performance and eliminate certain charges that management believes do not reflect the Company’s operations and underlying operational performance. The compensation committee of the Company’s board of directors also uses certain of these measures to evaluate management’s performance and set its compensation. The Company believes that these non-GAAP measures also provide useful information to investors regarding certain financial and business trends relating to the Company’s financial condition and operating results facilitates an evaluation of the financial performance of the Company and its operations on a consistent basis. Providing this information therefore allows investors to make independent assessments of the Company’s financial performance, results of operations and trends while viewing the information through the eyes of management.

 

These non-GAAP measures are subject to limitations. The non-GAAP measures presented in this release may not be comparable to similarly titled measures used by other companies because other companies may not calculate one or more in the same manner. Additionally, the non-GAAP performance measures exclude significant expenses and income that are required by GAAP to be recorded in the Company’s financial statements; do not reflect changes in, or cash requirements for, working capital needs; and do not reflect interest expense, or the requirements necessary to service interest or principal payments on debt. Further, our historical adjusted results are not intended to project our adjusted results of operations or financial position for any future period. To compensate for these limitations, management presents and considers these non-GAAP measures in conjunction with the Company’s GAAP results; no non-GAAP measure should be considered in isolation from or as alternatives to any measure determined in accordance with GAAP. Readers should review the reconciliations included below, and should not rely on any single financial measure to evaluate the Company’s business.

 

A reconciliation of each historical non-GAAP measure to the most directly comparable GAAP measure is set forth below.

 

Amneal Pharmaceuticals, Inc.

Consolidated Statements of Operations

(Unaudited; In thousands, except per share amounts)

Three Months Ended March 31,

2023

2022

Net revenue

$

557,540

$

497,633

Cost of goods sold

379,354

323,062

Gross profit

178,186

174,571

Selling, general and administrative

102,096

98,665

Research and development

38,690

52,798

Intellectual property legal development expenses

1,644

764

Acquisition, transaction-related and integration expenses

434

Restructuring and other charges

510

731

Change in fair value of contingent consideration

2,457

200

Credit related to legal matters, net

(436)

(2,326)

Other operating income

(1,224)

Operating income

34,449

23,305

Other (expense) income:

Interest expense, net

(49,315)

(33,335)

Foreign exchange gain (loss), net

1,901

(2,013)

Other income, net

3,539

2,122

Total other expense, net

(43,875)

(33,226)

Loss before income taxes

(9,426)

(9,921)

Provision for (benefit from) income taxes

668

(3,461)

Net loss

(10,094)

(6,460)

Less: Net loss attributable to non-controlling interests

3,151

4,742

Net loss attributable to Amneal Pharmaceuticals, Inc. before accretion of redeemable

non-controlling interest

(6,943)

(1,718)

Accretion of redeemable non-controlling interest

(438)

Net loss attributable to Amneal Pharmaceuticals, Inc.

$

(6,943)

$

(2,156)

Net loss per share attributable to Amneal Pharmaceuticals, Inc.’s class A common stockholders:

Basic and diluted

$

(0.05)

$

(0.01)

Weighted-average common shares outstanding:

Basic and diluted

152,109

149,892

Amneal Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(Unaudited; In thousands)

March 31, 2023

December 31, 2022

Assets

Current assets:

Cash and cash equivalents

$

144,674

$

25,976

Restricted cash

6,395

9,251

Trade accounts receivable, net

545,760

741,791

Inventories

529,042

530,735

Prepaid expenses and other current assets

81,424

103,565

Related party receivables

30

500

Total current assets

1,307,325

1,411,818

Property, plant and equipment, net

462,606

469,815

Goodwill

599,156

598,853

Intangible assets, net

1,055,319

1,096,093

Operating lease right-of-use assets

36,127

38,211

Operating lease right-of-use assets – related party

17,244

17,910

Financing lease right-of-use assets

62,400

63,424

Other assets

86,428

103,217

Total assets

$

3,626,605

$

3,799,341

Liabilities and Stockholders’ Equity

Current liabilities:

Accounts payable and accrued expenses

$

467,421

$

538,199

Current portion of liabilities for legal matters

76,317

107,483

Revolving credit facility

100,000

60,000

Current portion of long-term debt, net

29,965

29,961

Current portion of operating lease liabilities

9,017

8,321

Current portion of operating lease liabilities – related party

2,930

2,869

Current portion of financing lease liabilities

3,309

3,488

Related party payables – short term

14,750

2,479

Total current liabilities

703,709

752,800

Long-term debt, net

2,561,724

2,591,981

Note payable – related party

40,128

39,706

Operating lease liabilities

30,782

32,126

Operating lease liabilities – related party

15,163

15,914

Financing lease liabilities

60,241

60,769

Related party payables – long term

11,207

9,649

Other long-term liabilities

41,456

87,468

Total long-term liabilities

2,760,701

2,837,613

Redeemable non-controlling interests

27,527

24,949

Total stockholders’ equity

134,668

183,979

Total liabilities and stockholders’ equity

$

3,626,605

$

3,799,341

Amneal Pharmaceuticals, Inc.

Consolidated Statements of Cash Flows

(Unaudited; In thousands)

Three Months Ended March 31,

2023

2022

Cash flows from operating activities:

Net loss

$

(10,094)

$

(6,460)

Adjustments to reconcile net loss to net cash provided by operating activities:

Depreciation and amortization

58,150

57,815

Unrealized foreign currency (gain) loss

(1,987)

3,140

Amortization of debt issuance costs and discount

2,058

2,195

Change in fair value of contingent consideration

2,457

200

Stock-based compensation

7,596

8,065

Inventory provision

25,204

3,578

Other operating charges and credits, net

2,047

1,155

Changes in assets and liabilities:

Trade accounts receivable, net

195,970

124,268

Inventories

(22,508)

(25,549)

Prepaid expenses, other current assets and other assets

29,160

(4,423)

Related party receivables

470

4

Accounts payable, accrued expenses and other liabilities

(150,483)

(48,777)

Related party payables

1,672

5,132

Net cash provided by operating activities

139,712

120,343

Cash flows from investing activities:

Purchases of property, plant and equipment

(9,688)

(10,793)

Acquisition of business

(84,714)

Acquisition of intangible assets

(338)

Deposits for future acquisition of property, plant, and equipment

(1,711)

(1,888)

Net cash used in investing activities

(11,737)

(97,395)

Cash flows from financing activities:

Payments of principal on debt, revolving credit facility, financing leases and other

(72,659)

(9,796)

Borrowings on revolving credit facility

80,000

Proceeds from exercise of stock options

111

Employee payroll tax withholding on restricted stock unit vesting

(2,022)

(3,001)

Payments of deferred consideration for acquisitions – related party

(43,998)

Acquisition of redeemable non-controlling interest

(1,722)

Tax distributions to non-controlling interests

(18,219)

(3,164)

Net cash used in financing activities

(12,900)

(61,570)

Effect of foreign exchange rate on cash

767

(1,572)

Net increase (decrease) in cash, cash equivalents, and restricted cash

115,842

(40,194)

Cash, cash equivalents, and restricted cash – beginning of period

35,227

256,739

Cash, cash equivalents, and restricted cash – end of period

$

151,069

$

216,545

Cash and cash equivalents – end of period

$

144,674

$

210,477

Restricted cash – end of period

6,395

6,068

Cash, cash equivalents, and restricted cash – end of period

$

151,069

$

216,545

Amneal Pharmaceuticals, Inc.

Non-GAAP Reconciliations

(Unaudited, In thousands)

Reconciliation of Net Loss to EBITDA and Adjusted EBITDA

Three Months Ended March 31,

2023

2022

Net loss

$

(10,094)

$

(6,460)

Adjusted to add:

Interest expense, net

49,315

33,335

Provision for (benefit from) income taxes

668

(3,461)

Depreciation and amortization

58,150

57,815

EBITDA (Non-GAAP)

$

98,039

$

81,229

Adjusted to add (deduct):

Stock-based compensation expense

7,596

8,065

Acquisition, site closure, and idle facility expenses (1)

2,701

5,589

Restructuring and other charges

411

731

Charges (credits) related to legal matters, net (2)

4,064

(2,326)

Asset impairment charges

733

Foreign exchange (gain) loss

(1,901)

2,013

Change in fair value of contingent consideration

2,457

200

Regulatory approval milestone

5,000

Other

2,080

(641)

Adjusted EBITDA (Non-GAAP)

$

116,180

$

99,860

Amneal Pharmaceuticals, Inc.

Non-GAAP Reconciliations

(Unaudited; In thousands, except per share amounts)

Reconciliation of Net Loss to Adjusted Net Income and Calculation of Adjusted Diluted Earnings Per Share

Three Months Ended March 31,

2023

2022

Net loss

$

(10,094)

$

(6,460)

Adjusted to add (deduct):

Non-cash interest

1,841

1,982

GAAP provision for (benefit from) income taxes

668

(3,461)

Amortization

39,611

39,152

Stock-based compensation expense

7,596

8,065

Acquisition, site closure expenses, and idle facility expenses (1)

2,701

5,589

Restructuring and other charges

411

731

Charges (credits) related to legal matters, including interest, net (2)

4,882

(2,326)

Asset impairment charges

733

Regulatory approval milestone

5,000

Change in fair value of contingent consideration

2,457

200

Other

2,229

(500)

Provision for income taxes (3)

(10,829)

(10,185)

Net income attributable to non-controlling interests not associated with our

class B common stock

(5,395)

(2,199)

Adjusted net income (Non-GAAP)

$

36,811

$

35,588

Weighted average diluted shares outstanding (Non-GAAP) (4)

306,370

304,630

Adjusted diluted earnings per share (Non-GAAP)

$

0.12

$

0.12

Amneal Pharmaceuticals, Inc.

Non-GAAP Reconciliations

(Unaudited; In thousands)

Explanations for Reconciliations of Net Loss to EBITDA and Adjusted EBITDA and

Net Loss to Adjusted Net Income and Calculation of Adjusted Diluted Earnings per Share

(1)

Acquisition, site closure, and idle facility expenses for the three months ended March 31, 2023 primarily included site closure costs associated with the planned cessation of manufacturing at our Hauppauge, NY facility. Acquisition, site closure, and idle facility expenses for the three months ended March 31, 2022 primarily included (i) transaction and integration costs associated with the acquisition of the baclofen franchise from certain entities affiliated with Saol International Limited; (ii) integration costs associated with the acquisition of Puniska Healthcare Pvt. Ltd.; and (iii) site closure costs associated with the planned cessation of manufacturing at our Hauppauge, NY facility.

(2)

For the three months ended March 31, 2023 charges (credits) related to legal matters, net included charges of $4.9 million for legal proceedings. For the three months ended March 31, 2022, we recorded a net credit of $2.3 million for an insurance recovery of $4.0 million, partially offset by charges for legal proceedings.

(3)

The non-GAAP effective tax rates for the three months ended March 31, 2023 and 2022 were 22.7% and 22.3%, respectively.

(4)

Weighted average diluted shares outstanding consisted of class A common stock and class B common stock under the if-converted method.

Contacts

Anthony DiMeo

Head of Investor Relations

anthony.dimeo@amneal.com

Read full story here

Categories
Business Economics Lifestyle Regulations & Security

AM Best withdraws Credit Ratings of American Millennium Insurance Company and Citadel Reinsurance Company Limited

OLDWICK, N.J. — (BUSINESS WIRE) — AM Best has removed from under review with developing implications and downgraded the Financial Strength Rating (FSR) to D (Poor) from C- (Weak) and the Long-Term Issuer Credit Rating (Long-Term ICR) to “c” (Poor) from “cc” (Very Weak) of American Millennium Insurance Company (AMIC) (Bridgewater, NJ), a wholly owned subsidiary of Citadel Reinsurance Company Limited (Citadel Re) (Hamilton, Bermuda). The outlook assigned to these Credit Ratings (ratings) is negative.

Additionally, AM Best has removed from under review with developing implications and downgraded the FSR to C+ (Marginal) from B (Fair) and the Long-Term ICR to “b-” (Marginal) from “bb” (Fair) of Citadel Re. The outlook assigned to these ratings is negative. Concurrently, AM Best has withdrawn the ratings of AMIC and Citadel Re as the companies have requested to no longer participate in AM Best’s interactive rating process.

 

The ratings of AMIC reflect its balance sheet strength, which AM Best assesses as very weak, as well as its weak operating performance, limited business profile and marginal enterprise risk management (ERM).

 

The ratings of Citadel Re reflect its balance sheet strength, which AM Best assesses as weak, as well as its marginal operating performance, limited business profile and marginal ERM.

 

Prior to these rating actions, AM Best downgraded the ratings of AMIC and Citadel Re in February 2021, and maintained the under review with negative implications status, resulting from persistent underwriting losses that negatively impacted the risk-adjusted capitalization of both companies. The under review status was pending due to a planned recapitalization of AMIC and Citadel Re to raise capital from outside investors.

 

In August 2021, Citadel Re completed its recapitalization of AMIC with a $6.2 million cash injection, raising the risk-based capital ratio to above 300% to the satisfaction of AMIC’s regulator, the Department of Banking and Insurance of New Jersey. However, management’s planned capital raise was not successful, as the transaction failed to get approval from the Bermuda Monetary Authority (BMA).

 

The failed transaction also led to Citadel Re having to return a portion of its capital to the outside investor and causing Citadel Re’s capital to fall below Bermuda’s Solvency Capital Requirement (SCR); consequently, the BMA ordered Citadel Re to stop writing any new and renewal business.

 

The downgrading of Citadel Re’s ratings reflects its weakened balance sheet strength, as well as a lower assessment of its business profile due to its run-off status. The downgrading of AMIC’s ratings is mainly due to it no longer receiving lift from Citadel Re, because of Citadel Re’s diminished capital position. The negative outlooks on both entities reflect the uncertainty surrounding their future business prospects and the challenges associated with the regulatory and capital requirements imposed on Citadel Re by the BMA.

 

This press release relates to Credit Ratings that have been published on AM Best’s website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please see AM Best’s Recent Rating Activity web page. For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best’s Credit Ratings. For information on the proper use of Best’s Credit Ratings, Best’s Performance Assessments, Best’s Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best’s Ratings & Assessments.

 

AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit www.ambest.com.

 

Copyright © 2023 by A.M. Best Rating Services, Inc. and/or its affiliates. ALL RIGHTS RESERVED.

Contacts

Jieqiu Fan
Associate Director
+1 908 439 2200, ext. 5372
jieqiu.fan@ambest.com

Christopher Sharkey
Associate Director, Public Relations
+1 908 439 2200, ext. 5159
christopher.sharkey@ambest.com

Daniel Ryan
Senior Director

+1 908 439 2200, ext. 5325
daniel.ryan@ambest.com

Al Slavin
Senior Public Relations Specialist
+1 908 439 2200, ext. 5098
al.slavin@ambest.com

Categories
Business Economics Lifestyle Perks Special/Sponsored Content Sports & Gaming

Traverse City Whiskey Co. nominated as a ‘Best in Class’ finalist, awarded three double gold medals at the 2023 San Francisco World Spirits Competition

Amongst Thousands of Entries, TCWC’s Barrel Proof Bourbon Once Again Selected as a Top Three Finalist For “Best Small Batch Bourbon,” Which it Won in 2019

 

TRAVERSE CITY, Mich. — (BUSINESS WIRE) — #barrellproofryeTraverse City Whiskey Co. (TCWC), a true small batch distillery handcrafting a portfolio of premium whiskies and bourbons in Up North Michigan, announced that three of its signature products – Barrel Proof Bourbon Whiskey, Barrel Proof Rye Whiskey and Sherry Barrel Finished Bourbon – were awarded Double Gold medals at the prestigious 2023 San Francisco World Spirits Competition. Additionally, TCWC’s Barrel Proof Bourbon was named a Finalist for “Best Small Batch Bourbon,” an award which it won in 2019.


TCWC’s Barrel Proof Bourbon Whiskey has quickly become a must have for premium bourbon lovers. It has a truly exhilarating taste, like hugging a bear, but way less dangerous. It contains a mashbill of 75% corn, 21% rye and 4% malted barley that was aged for 10 years and bottled at 120.2 proof (60.1% ABV). The bourbon presents a deep, oaky body with sweet and nutty flavors of burnt caramel and dark chocolate, a smooth and creamy mouthfeel, and a long finish. SRP $80.

 

The company’s Barrel Proof Rye is the newest addition to the company’s already impressive lineup. Imagine a red-bearded pirate crying tears of joy after seeing land for the first time in 10 years. That’s the feeling whiskey lovers can expect when drinking it. The expression has a mashbill of 95% rye and 5% malted barley. The expression was aged for six years and bottled at 116.6 proof (58.3% ABV). The whiskey showcases a classic rye spice alongside a rich oak flavor, an effervescent aroma of baking spices, notes of allspice, black peppercorns and sage, and a warm buttery finish. SRP $80.

 

The Sherry Barrel Finished Bourbon tastes like a classy Cinco de Mayo party in your mouth. It is part of TCWC’s new “Finishing Series” that features a unique high-rye bourbon whiskey with a mashbill of 60% corn, 36% rye and 4% malted barley. The whiskey was aged for five years in new American Oak barrels and then rested in Pedro Ximenez sherry wine casks for nearly 12 months and bottled at 95 proof (47.5% ABV). It exemplifies notes of caramel, sassafras, cinnamon, raisins, and vanilla bean, with a mild finish of toasted rye bread and tobacco. SRP $60.

 

“It’s an absolute thrill to have our signature Barrel Proof Bourbon and Rye whiskeys receive Double Gold, and an honor to be a finalist for ‘Best Small Batch Bourbon’ for the second time,” said Chris Fredrickson, Co-founder, TCWC. “We’re also thrilled that our Sherry Barrel Finished whiskey, one of our newest products, also earned Double Gold.”

 

TCWC draws upon its early family roots in the distilled spirits industry dating back to the late 1800s, sourcing their grains from the Midwest. The distilling team, led by Chris Fredrickson, strives to make quality products, inspired by patented distilling techniques invented by Fredrickson’s great grandfather that were approved by the US PTO during the prohibition era.

 

TCWC products are available in 750ml bottles at both on- and off-premise establishments in the following markets: Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maryland, Michigan, Minnesota, Mississippi, Montana, Nebraska, Nevada, New Jersey, New York, North Carolina, Ohio, Pennsylvania, Tennessee, Texas, Utah, Washington, Washington DC, Wisconsin. Retail prices may vary by market.

 

For more information, please visit www.tcwhiskey.com and follow the brand on Facebook, Twitter, and Instagram @tcwhiskey.

 

About Traverse City Whiskey Co.

Traverse City Whiskey Co. is a family-owned distilled spirits company that is known for crafting premium whiskeys that are unmistakably Up North. The harsh winters and hot summers of Traverse City, Michigan, produce exceptional whiskeys forged by the elements. Up North whiskey is said to be both strong and delicate, like a lumberjack with an understanding gaze. TCWC’s early family roots are in the distilled spirits industry dating back to the late 1800’s, sourcing all grains from the Midwest.

 

Traverse City Whiskey Co. is a proud member of the Distilled Spirits Council of the United States (DISCUS).

Contacts

Aaron Brost | Ro-Bro Marketing & PR

312.576.5315 | aaron@ro-bro.com

Categories
Economics Healthcare Lifestyle Local News

Trenton employees receive a boost in healthcare

A Partnership with Healthcare2U Provides City Staff with Direct Primary Care Membership

 

AUSTIN, TX.  — City of Trenton employees are now benefiting from an enhanced healthcare plan.

 

The plan provides a Direct Primary Care (DPC) membership to city staff and aims to ensure that a visit to a doctor is affordable and accessible. Following a statewide increase in health premiums for state employees, Trenton sought options to ensure those costs remained low. As a result, they opted for a self-funded insurance plan through Aetna that included Healthcare2U’s DPC membership. This move is expected to save the city $4.3 million annually.

 

The added Healthcare2U DPC membership gives employees an excellent option for affordable access to physicians and internists. With an out-of-pocket cost of $0 for virtual primary care, $10 for an in-office acute consultation, and $25 for urgent care, the city believes this encourages employees to maintain a regular check-up routine while reducing overall claims costs.

 

“Our direct primary care model is the only one of its kind in the nation. We are in all 50 states and thanks to the brokers who see us as a valuable addition to their portfolio, we are quickly expanding throughout New Jersey,” said Andy Bonner, CEO of Healthcare2U. “Our team works with members to facilitate timely and frequent access to medical care that can be essential to the early detection of a serious condition.”

 

“We’re fortunate to be partnering with Healthcare2U for city staff with direct primary care membership, which helps to ensure that all of our city employees can access timely, affordable, and essential health services,” said Mayor Reed Gusciora. “We are projected to save millions of dollars through our new insurance policy and we’re so grateful to all of our partners for helping to make this a reality.”

 

DPC is not meant to be a substitute for major medical insurance, but it does have its advantages. The low cost of an office visit with DPC is meant to prompt individuals to see a doctor more often and avoid developing a serious complication with an unaddressed or undiagnosed issue. In addition to acute and urgent care visits, the plan offers:

  • Unlimited access to bilingual licensed medical providers online or by phone, 24/7/365 for minor illnesses and injuries at $0 out-of-pocket cost to members
  • Annual physical with four labs: complete metabolic panel (CMP), complete blood count (CBC), thyroid-stimulating hormone (TSH), and lipid panel
  • Unlimited chronic disease management for 13 prevalent chronic disease states within manageable ranges.

Healthcare2U partners with third-party administrators, carriers, and brokers to provide their clients with the DPC membership as a non-insurance alternative. These partnerships also allow Healthcare2U the unique opportunity to embed its services into valuable solutions that are available for wide distribution in the marketplaces.

 

Membership with the City of Trenton is established through Healthcare2U’s partnership with   Fairview Insurance.

About Healthcare2U

Healthcare2U is a membership-based, hybrid direct primary care (DPC) organization that ensures employers of all sizes and structures have nationwide access to affordable, consistent, and quality primary care over 40% below the average cost of traditional DPC practices operating in the market today. Through our proprietary Private Physician Network (PPN)™, Healthcare2U promotes healthy living by detecting, treating, and managing acute and chronic conditions before the onset of serious illness. Healthcare2U is headquartered in Austin, Texas, and is available nationwide. For more information, visitwww.healthc2u.com. Follow us on Twitter @Healthc2U and on LinkedIn at Healthcare2U. 

About Fairview Insurance

Fairview Insurance is a full-service insurance agency based in Verona and Cherry Hill, New Jersey. Working on behalf of individuals, companies, and public entities, we provide customized insurance plans, employee benefits, and financial planning services. Our longevity and depth of experience have fostered a solid reputation for friendly, personal service that forms the core of our success.

 

Follow our updates and join the discussion on Healthcare2U’s LinkedIn page

Categories
Business Economics Environment Lifestyle Special/Sponsored Content

American Water reports strong first quarter 2023 results; affirms 2023 guidance and long-term targets

  • First quarter 2023 earnings of $0.91 per share, compared to $0.87 per share in 2022
  • 2023 earnings per share guidance range of $4.72 to $4.82 affirmed, long-term targets also affirmed
  • Invested $538 million in the first three months of the year; total capital plan on track to invest approximately $2.9 billion in 2023
  • Sold 12,650,000 shares of common stock on March 3, 2023, for net proceeds of approximately $1.7 billion
  • Announced agreements to purchase the assets related to the wastewater system of Towamencin Municipal Authority in Pennsylvania for a purchase price of $104 million and the wastewater treatment plant from Granite City in Illinois for a purchase price of $83 million
  • Published the 2022 Environmental, Social and Governance Data Summary and the Inclusion, Diversity & Equity Summary, part of the Company’s commitment to data transparency and sharing timely information on key ESG and diversity metrics

 

CAMDEN, N.J. — (BUSINESS WIRE) — American Water Works Company, Inc. (NYSE: AWK) today reported results for the quarter ended March 31, 2023, of $0.91 per share, compared to $0.87 per share in 2022.

 

“We’re off to a great start to the year,” said M. Susan Hardwick, president and CEO of American Water. “Our investments in infrastructure and our success signing new purchase agreements for regulated acquisitions has set the stage well for achieving our expected growth in 2023 and beyond.”

 

“We also successfully executed the 2023 planned equity issuance in March. In total $1.7 billion was issued, reflecting an upsized offering made possible by very strong demand for our securities. We are very pleased with the interest by investors in the company, both existing and new shareholders. Having the issue completed allows us to be very focused on executing on our plan. With this action and solid first quarter results, we are on track to meet our 2023 objectives,” said Hardwick.

 

2023 EPS Guidance and Long-Term Financial Targets Affirmed

The Company affirms its 2023 earnings per share guidance range of $4.72 to $4.82. The Company also affirms its long-term financial targets for the 2023-2027 period announced in Nov. 2022, including its long-term EPS and dividend growth rate targets of 7-9%. The Company’s earnings forecasts are subject to numerous risks and uncertainties, including, without limitation, those described under “Cautionary Statement Concerning Forward-Looking Statements” below and under “Risk Factors” in its annual, quarterly, and current reports filed with the Securities and Exchange Commission (“SEC”). All statements related to earnings and earnings per share refer to diluted earnings and earnings per share.

 

Consolidated Results

For the three months ended March 31, 2023, earnings per share were $0.91, compared to $0.87 per share in the same period in 2022. These increases were primarily driven by the implementation of new rates in the Regulated Businesses for the recovery of capital and acquisition investments, offset somewhat by impacts from inflationary pressures on production costs and higher interest costs since mid-2022. Approximately 75% of the estimated impact of inflation on chemicals, power and other fuel, and from higher pension costs and interest rates, are reflected in higher revenues in 2023 from rate cases recently completed.

 

The Company is on track to meet its capital investment plan for the year with investments of $538 million in the first three months of 2023, including $532 million for infrastructure improvements and replacements in the Regulated Businesses. The Company plans to invest a total of approximately $2.9 billion across its footprint in 2023, including approximately $0.4 billion for acquisitions. As of March 31, 2023, the Company had $481 million of acquisitions under agreement, including Pennsylvania American Water’s agreement announced in March 2023 to purchase the wastewater system assets of Towamencin Township for $104 million. In addition, in April 2023, Illinois American Water announced an agreement to purchase the assets of the wastewater treatment plant from Granite City for $83 million, adding further to the Company’s acquisitions under agreement.

 

Regulated Businesses

In the first quarter of 2023, Regulated Businesses’ net income was $174 million, compared to $160 million for the same period in 2022.

 

Operating revenues increased $82 million for the three months ended March 31, 2023, as compared to 2022. The increase in operating revenues was primarily a result of authorized revenue increases from completed general rate cases and infrastructure proceedings for the recovery of incremental capital and acquisition investments.

 

To date, the Company has been authorized additional annualized revenues of approximately $229 million from general rate cases in 2023. Further, approximately $50 million of additional annualized revenues from infrastructure surcharges have been authorized and are effective in 2023. The Company has general rate cases in progress in three jurisdictions, and has filed for infrastructure surcharges in two jurisdictions, reflecting a total annualized revenue request of approximately $144 million.

 

Operation and maintenance (“O&M”) expenses were higher by $15 million for the three months ended March 31, 2023, as compared to 2022, primarily due to increases in production costs from inflationary pressures that began to accelerate in mid-2022. Depreciation expense was higher by $14 million in the same period due to the growing capital investment. Also, interest expense was higher by $17 million due to additional long-term debt and higher rates on short-term debt.

 

For the 12-month period ended March 31, 2023, the Company’s adjusted regulated O&M efficiency ratio (a non-GAAP financial measure) was 33.6%, compared to 33.9% for the 12-month period ended March 31, 2022. The ratio reflects an increase in operating revenues for the Regulated Businesses, after considering the adjustment for the amortization of the excess accumulated deferred income taxes (“EADIT”) shown in the table below, as well as the continued focus on operating costs.

 

Dividends

On March 1, 2023, the Company paid a quarterly cash dividend of $0.6550 per share to shareholders of record as of February 7, 2023.

On April 26, 2023, the Company’s Board of Directors declared a quarterly cash dividend payment of $0.7075 per share of common stock, an 8.0% increase over the prior quarterly dividend, payable on June 1, 2023, to shareholders of record as of May 9, 2023.

 

2023 First Quarter Earnings Conference Call

The conference call to discuss first quarter 2023 earnings will take place on Thursday, April 27, 2023, at 9 a.m. Eastern Daylight Time. Interested parties may listen to an audio webcast through a link on the Company’s Investor Relations website at ir.amwater.com. Presentation slides that will be used in conjunction with the earnings conference call will also be made available online in advance at ir.amwater.com. The Company recognizes its website as a key channel of distribution to reach public investors and as a means of disclosing material non-public information to comply with its obligations under SEC Regulation FD.

 

Following the earnings conference call, a replay of the audio webcast will be available for one year on American Water’s investor relations website at ir.amwater.com/events.

 

Non-GAAP Financial Measures

This press release includes a presentation of adjusted regulated O&M efficiency ratio, a “non-GAAP financial measure” under SEC rules, which excludes from its calculation estimated purchased water revenues and purchased water expenses, reductions for the amortization of EADIT, and the allocable portion of non-O&M support services costs, mainly depreciation and general taxes. These items were excluded from the O&M efficiency ratio calculation as they do not reflect management’s ability to increase the efficiency of the Regulated Businesses. This item is derived from American Water’s consolidated financial information but is not presented in its financial statements prepared in accordance with GAAP. This non-GAAP financial measure supplements and should be read in conjunction with the Company’s GAAP disclosures and should be considered as an addition to, and not a substitute for, any GAAP measure.

 

Management evaluates its operating performance using this ratio and believes that this non-GAAP financial measure is useful to the Company’s investors because it directly measures improvement in the operating performance and efficiency of the Company’s Regulated Businesses. The Company’s adjusted regulated O&M efficiency ratio (i) is not an accounting measure that is based on GAAP; (ii) is not based on a standard, objective industry definition or method of calculation; (iii) may not be comparable to other companies’ operating measures; and (iv) should not be used in place of the GAAP information provided elsewhere in this press release.

 

Set forth in this release is a table that calculates the Company’s adjusted regulated O&M efficiency ratio and reconciles each of the components used to calculate this ratio to the most directly comparable GAAP financial measure.

 

About American Water

With a history dating back to 1886, American Water is the largest and most geographically diverse U.S. publicly-traded water and wastewater utility company. The Company employs approximately 6,500 dedicated professionals who provide regulated and market-based drinking water, wastewater and other related services to over 14 million people in 24 states. More information can be found by visiting amwater.com and follow American Water on Twitter, Facebook and LinkedIn.

 

Throughout this press release, unless the context otherwise requires, references to the “Company” and “American Water” mean American Water Works Company, Inc. and all of its subsidiaries, taken together as a whole.

 

Cautionary Statement Concerning Forward-Looking Statements

Certain statements in this press release including, without limitation, 2023 earnings guidance, the Company’s long-term financial, growth and dividend targets, future capital needs, the ability to achieve the Company’s strategies and goals, including with respect to its ESG focus, the outcome of the Company’s pending acquisition activity, the amount and allocation of projected capital expenditures, and estimated revenues from rate cases and other government agency authorizations, are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. In some cases, these forward-looking statements can be identified by words with prospective meanings such as “intend,” “plan,” “estimate,” “believe,” “anticipate,” “expect,” “predict,” “project,” “propose,” “assume,” “forecast,” “outlook,” “likely,” “uncertain,” “future,” “pending,” “goal,” “objective,” “potential,” “continue,” “seek to,” “may,” “can,” “will,” “should” and “could” and or the negative of such terms or other variations or similar expressions. These forward-looking statements are predictions based on American Water’s current expectations and assumptions regarding future events. They are not guarantees or assurances of any outcomes, financial results, levels of activity, performance or achievements, and readers are cautioned not to place undue reliance upon them. The forward-looking statements are subject to a number of estimates and assumptions, and known and unknown risks, uncertainties and other factors. Actual results may differ materially from those discussed in the forward-looking statements included in this press release as a result of the factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, and subsequent filings with the SEC, and because of factors such as: the decisions of governmental and regulatory bodies, including decisions to raise or lower customer rates; the timeliness and outcome of regulatory commissions’ and other authorities’ actions concerning rates, capital structure, authorized return on equity, capital investment, system acquisitions and dispositions, taxes, permitting, water supply and management, and other decisions; changes in customer demand for, and patterns of use of, water and energy, such as may result from conservation efforts, or otherwise; a loss of one or more large industrial or commercial customers due to adverse economic conditions, or other factors; limitations on the availability of the Company’s water supplies or sources of water, or restrictions on its use thereof, resulting from allocation rights, governmental or regulatory requirements and restrictions, drought, overuse or other factors; changes in laws, governmental regulations and policies, including with respect to the environment, health and safety, data and consumer privacy, security and protection, water quality and water quality accountability, contaminants of emerging concern, public utility and tax regulations and policies, and impacts resulting from U.S., state and local elections and changes in federal, state and local executive administrations; the Company’s ability to collect, distribute, use, secure and store consumer data in compliance with current or future governmental laws, regulation and policies with respect to data and consumer privacy, security and protection; weather conditions and events, climate variability patterns, and natural disasters, including drought or abnormally high rainfall, prolonged and abnormal ice or freezing conditions, strong winds, coastal and intercoastal flooding, pandemics (including COVID-19) and epidemics, earthquakes, landslides, hurricanes, tornadoes, wildfires, electrical storms, sinkholes and solar flares; the outcome of litigation and similar governmental and regulatory proceedings, investigations or actions; the risks associated with the Company’s aging infrastructure, and its ability to appropriately improve the resiliency of, or maintain and replace, current or future infrastructure and systems, including its technology and other assets, and manage the expansion of its businesses; exposure or infiltration of the Company’s technology and critical infrastructure systems, including the disclosure of sensitive, personal or confidential information contained therein, through physical or cyber attacks or other means; the Company’s ability to obtain permits and other approvals for projects and construction of various water and wastewater facilities; changes in the Company’s capital requirements; the Company’s ability to control operating expenses and to achieve operating efficiencies; the intentional or unintentional actions of a third party, including contamination of the Company’s water supplies or the water provided to its customers; the Company’s ability to obtain and have delivered adequate and cost-effective supplies of pipe, equipment (including personal protective equipment), chemicals, power and other fuel, water and other raw materials and to address or mitigate supply chain constraints that may result in delays or shortages in, as well as increased costs of, supplies, products and materials that are critical to or used in the Company’s business operations; the Company’s ability to successfully meet its operational growth projections, either individually or in the aggregate, and capitalize on growth opportunities, including, among other things, with respect to acquiring, closing and successfully integrating regulated operations, the Company’s Military Services Group entering into new military installation contracts, price redeterminations and other agreements and contracts with the U.S. government, and realizing anticipated benefits and synergies from new acquisitions; risks and uncertainties following the completion of the sale of the Company’s former Homeowner Services Group (“HOS”), including the Company’s ability to receive contingent consideration provided for in the HOS sale as well as amounts due, payable and owing to the Company under the seller note when due, and the ability of the Company to redeploy successfully and timely the net proceeds of this transaction into the Company’s Regulated Businesses; risks and uncertainties associated with contracting with the U.S. government, including ongoing compliance with applicable government procurement and security regulations; cost overruns relating to improvements in or the expansion of the Company’s operations; the Company’s ability to successfully develop and implement new technologies and to protect related intellectual property; the Company’s ability to maintain safe work sites; the Company’s exposure to liabilities related to environmental laws and similar matters resulting from, among other things, water and wastewater service provided to customers; the ability of energy providers, state governments and other third parties to achieve or fulfill their greenhouse gas emission reduction goals, including without limitation through state renewable portfolio standards and carbon transition plans; changes in general economic, political, business and financial market conditions; access to sufficient debt and/or equity capital on satisfactory terms and as needed to support operations and capital expenditures; fluctuations in inflation or interest rates and the Company’s ability to address or mitigate the impacts thereof; the ability to comply with affirmative or negative covenants in the current or future indebtedness of the Company or any of its subsidiaries, or the issuance of new or modified credit ratings or outlooks or other communications by credit rating agencies with respect to the Company or any of its subsidiaries (or any current or future indebtedness thereof), which could increase financing costs or funding requirements and affect the Company’s or its subsidiaries’ ability to issue, repay or redeem debt, pay dividends or make distributions; fluctuations in the value of, or assumptions and estimates related to, its benefit plan assets and liabilities, including with respect to its pension and other post-retirement benefit plans, that could increase expenses and plan funding requirements; changes in federal or state general, income and other tax laws, including (i) future significant tax legislation or regulations; and (ii) the availability of, or the Company’s compliance with, the terms of applicable tax credits and tax abatement programs; migration of customers into or out of the Company’s service territories and changes in water and energy consumption resulting therefrom; the use by municipalities of the power of eminent domain or other authority to condemn the systems of one or more of the Company’s utility subsidiaries, or the assertion by private landowners of similar rights against such utility subsidiaries; any difficulty or inability to obtain insurance for the Company, its inability to obtain insurance at acceptable rates and on acceptable terms and conditions, or its inability to obtain reimbursement under existing or future insurance programs and coverages for any losses sustained; the incurrence of impairment charges, changes in fair value and other adjustments related to the Company’s goodwill or the value of its other assets; labor actions, including work stoppages and strikes; the Company’s ability to retain and attract highly qualified and skilled employees and/or diverse talent; civil disturbances or unrest, or terrorist threats or acts, or public apprehension about future disturbances, unrest, or terrorist threats or acts; and the impact of new, and changes to existing, accounting standards.

 

These forward-looking statements are qualified by, and should be read together with, the risks and uncertainties set forth above and the risk factors included in American Water’s annual, quarterly and other SEC filings, and readers should refer to such risks, uncertainties and risk factors in evaluating such forward-looking statements. Any forward-looking statements American Water makes speak only as of the date of this press release. American Water does not have or undertake any obligation or intention to update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, except as otherwise required by the federal securities laws. New factors emerge from time to time, and it is not possible for the Company to predict all such factors. Furthermore, it may not be possible to assess the impact of any such factor on the Company’s businesses, either viewed independently or together, or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. The foregoing factors should not be construed as exhaustive.

 

AWK-IR

American Water Works Company, Inc. and Subsidiary Companies

Consolidated Statements of Operations (Unaudited)

(In millions, except per share data)

For the Three Months Ended March 31,

2023

2022

Operating revenues

$

938

$

842

Operating expenses:

Operation and maintenance

393

364

Depreciation and amortization

172

158

General taxes

78

74

Total operating expenses, net

643

596

Operating income

295

246

Other income (expense):

Interest expense

(115

)

(100

)

Interest income

14

13

Non-operating benefit costs, net

9

19

Other, net

11

15

Total other (expense) income

(81

)

(53

)

Income before income taxes

214

193

Provision for income taxes

44

35

Net income attributable to common shareholders

$

170

$

158

Basic earnings per share:

Net income attributable to common shareholders

$

0.91

$

0.87

Diluted earnings per share:

Net income attributable to common shareholders

$

0.91

$

0.87

Weighted-average common shares outstanding:

Basic

186

182

Diluted

186

182

American Water Works Company, Inc. and Subsidiary Companies

Consolidated Balance Sheets (Unaudited)

(In millions, except share and per share data)

March 31, 2023

December 31, 2022

ASSETS

Property, plant and equipment

$

30,214

$

29,736

Accumulated depreciation

(6,582

)

(6,513

)

Property, plant and equipment, net

23,632

23,223

Current assets:

Cash and cash equivalents

213

85

Restricted funds

29

32

Accounts receivable, net of allowance for uncollectible accounts of $55 and $60, respectively

318

334

Income tax receivable

96

114

Unbilled revenues

289

275

Materials and supplies

103

98

Other

290

312

Total current assets

1,338

1,250

Regulatory and other long-term assets:

Regulatory assets

1,004

990

Seller promissory note from the sale of the Homeowner Services Group

720

720

Operating lease right-of-use assets

83

82

Goodwill

1,143

1,143

Other

366

379

Total regulatory and other long-term assets

3,316

3,314

Total assets

$

28,286

$

27,787

American Water Works Company, Inc. and Subsidiary Companies

Consolidated Balance Sheets (Unaudited)

(In millions, except share and per share data)

March 31, 2023

December 31, 2022

CAPITALIZATION AND LIABILITIES

Capitalization:

Common stock ($0.01 par value; 500,000,000 shares authorized; 200,058,247 and 187,200,539 shares issued, respectively)

$

2

$

2

Paid-in-capital

8,519

6,824

Retained earnings

1,437

1,267

Accumulated other comprehensive loss

(23

)

(23

)

Treasury stock, at cost (5,414,795 and 5,342,477 shares, respectively)

(388

)

(377

)

Total common shareholders’ equity

9,547

7,693

Long-term debt

10,485

10,926

Redeemable preferred stock at redemption value

2

3

Total long-term debt

10,487

10,929

Total capitalization

20,034

18,622

Current liabilities:

Short-term debt

1,175

Current portion of long-term debt

727

281

Accounts payable

193

254

Accrued liabilities

561

706

Accrued taxes

74

49

Accrued interest

114

91

Other

223

255

Total current liabilities

1,892

2,811

Regulatory and other long-term liabilities:

Advances for construction

321

316

Deferred income taxes and investment tax credits

2,483

2,437

Regulatory liabilities

1,568

1,590

Operating lease liabilities

70

70

Accrued pension expense

215

235

Other

192

202

Total regulatory and other long-term liabilities

4,849

4,850

Contributions in aid of construction

1,511

1,504

Commitments and contingencies

Total capitalization and liabilities

$

28,286

$

27,787

Contacts

Investor Contact:
Aaron Musgrave

Vice President, Investor Relations

856-955-4029

aaron.musgrave@amwater.com

Media Contact:
Maureen Duffy

Senior Vice President, Communications and External Affairs

856-955-4163

maureen.duffy@amwater.com

Read full story here

Categories
Business Economics Environment Lifestyle

American Water increases dividend 8.0 percent

CAMDEN, N.J. — (BUSINESS WIRE) — American Water Works Company, Inc. (NYSE: AWK) announced today that its board of directors declared a quarterly cash dividend payment of $0.7075 per share of common stock, an increase of 8.0 percent.

 

“American Water continues to be an industry leader in dividend growth, which is a result of our continued successful execution of key strategic initiatives and the strength of our financial outlook,” said M. Susan Hardwick, president and chief executive officer of American Water. “We recognize the value of our dividend growth and the role it has played in delivering exceptional shareholder value.”

 

The company expects to continue its dividend growth within a 7 to 9 percent range over the long term, with a target dividend payout ratio of between 55 and 60 percent of earnings. The company has paid dividends at a compound annual growth rate of nearly 9.7 percent over the last five years.

 

The increased quarterly dividend will be payable on June 1, 2023, to all shareholders of record as of May 9, 2023.

 

American Water offers a dividend reinvestment and direct stock purchase plan called American Water Stock Direct (the “Plan”), which enables shareholders to reinvest cash dividends and purchase additional shares of American Water common stock without any brokerage commissions or service charges. Shareholders and other persons may obtain a copy of the Plan prospectus and an enrollment form by contacting American Stock Transfer & Trust Company (“AST”) at 888-556-0423, visiting AST’s website at www.astfinancial.com, contacting American Water’s Investor Relations department at 856-566-4005 or by visiting the Investor Relations webpage located at ir.amwater.com.

 

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities. The offer is being made solely through the Plan prospectus.

 

About American Water

With a history dating back to 1886, American Water (NYSE: AWK) is the largest and most geographically diverse U.S. publicly traded water and wastewater utility company. The company employs approximately 6,500 dedicated professionals who provide regulated and regulated-like drinking water and wastewater services to an estimated 14 million people in 24 states. American Water provides safe, clean, affordable, and reliable water services to our customers to help keep their lives flowing. For more information, visit amwater.com and diversityataw.com. Follow American Water on Twitter, Facebook and LinkedIn.

AWK-IR

Contacts

Investor Contact:
Aaron Musgrave

Vice President, Investor Relations

(856) 955-4029

aaron.musgrave@amwater.com

Media Contact:
Maureen Duffy

Senior Vice President, Communications and External Affairs

(856) 955-4163

maureen.duffy@amwater.com

Categories
Business Economics Healthcare Lifestyle Perks Regulations & Security Science Travel & Leisure

Johnson & Johnson announces launch of Kenvue Inc. IPO roadshow

NEW BRUNSWICK, N.J. — (BUSINESS WIRE) — Johnson & Johnson (NYSE: JNJ) today announced that Kenvue Inc. “(Kenvue),” a wholly owned subsidiary of Johnson & Johnson comprising its Consumer Health Business, has launched a roadshow for the initial public offering “(IPO)” of 151,204,000 shares of its common stock.

 

Kenvue expects to grant the underwriters a 30-day option to purchase up to an additional 22,680,600 shares of its common stock to cover over-allotments, if any. The IPO price is currently expected to be between $20.00 and $23.00 per share. Kenvue has applied to list its common stock on the New York Stock Exchange under the symbol “KVUE.”

 

After the completion of the IPO, Johnson & Johnson will own 1,716,160,000 shares of Kenvue’s common stock, representing 91.9% of the total outstanding shares of Kenvue’s common stock (or 90.8% if the underwriters exercise in full their over-allotment option).

 

Goldman Sachs & Co. LLC, J.P. Morgan and BofA Securities are acting as joint lead book-running managers for the IPO. Citigroup, Deutsche Bank Securities, BNP Paribas, HSBC, RBC Capital Markets and UBS Investment Bank are acting as book-running managers for the IPO and BBVA, ING, IMI – Intesa Sanpaolo, Santander, UniCredit Capital Markets, Academy Securities, Independence Point Securities, Ramirez & Co., Inc., R. Seelaus & Co., LLC and Siebert Williams Shank are acting as co-managers for the IPO.

 

A registration statement on Form S-1 relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. The IPO will be made only by means of a prospectus. A copy of the preliminary prospectus relating to the IPO may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316, or by emailing: prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-866-803-9204, or by emailing: prospectus-eq_fi@jpmchase.com; or BofA Securities, NC1-022-02-25, Attention: Prospectus Department, 201 North Tryon Street, Charlotte, North Carolina 28255, telephone: 1-800-294-1322, or by emailing: dg.prospectus_requests@bofa.com.

 

This press release is neither an offer to sell nor a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful.

 

About Johnson & Johnson

At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 135 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest, most diversified healthcare products company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.

 

Cautions Concerning Forward-Looking Statements

This release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: the timing and details of the IPO, the number of shares to be offered in the IPO, the expected price at which such shares will be offered, the grant of the over-allotment option and whether the underwriters will exercise such option, the number of shares to be held by Johnson & Johnson following the IPO and the expectations relating to the listing of Kenvue’s common stock on the New York Stock Exchange. Readers are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: Johnson & Johnson’s ability to satisfy the necessary conditions to consummate the separation of Kenvue on a timely basis or at all; Johnson & Johnson’s ability to successfully separate Kenvue and realize the anticipated benefits from the separation; Kenvue’s ability to succeed as a standalone publicly traded company; economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including unexpected clinical trial results, additional analysis of existing clinical data, uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; the impact of business combinations and divestitures; challenges to patents; the impact of patent expirations; the ability of Johnson & Johnson to successfully execute strategic plans, including restructuring plans; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws, global health care reforms and import/export and trade laws; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 1, 2023, including in the section captioned “Cautionary Note Regarding Forward-Looking Statements”, and in Johnson & Johnson’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this press release speaks only as of the date of this press release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

Contacts

Investor Relations:
Jessica Moore (Johnson & Johnson)

investor-relations@its.jnj.com

Tina Romani (Kenvue)

Kenvue_IR@kenvue.com